Literature DB >> 25267766

Regulatory decisions pertaining to aprotinin may be putting patients at risk.

Paul C Hébert1, Dean A Fergusson2, Brian Hutton1, C David Mazer1, Stephen Fremes1, Morris Blajchman1, Charles MacAdams1, George Wells1, Jim Robblee1, Jean Bussières1, Kevin Teoh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25267766      PMCID： PMC4259771          DOI： 10.1503/cmaj.131582

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  19 in total

Review 1.  Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Artyom Sedrakyan; Tom Treasure; John A Elefteriades
Journal:  J Thorac Cardiovasc Surg       Date:  2004-09       Impact factor: 5.209

2.  Are tranexamic acid and ε-aminocaproic acid adequate substitutes for aprotinin?

Authors:  Deepak K Tempe; Suruchi Hasija
Journal:  Ann Card Anaesth       Date:  2012 Jan-Mar

Review 3.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis.

Authors:  Dean Fergusson; Shawn D Aaron; Gordon Guyatt; Paul Hébert
Journal:  BMJ       Date:  2002-09-21

Review 4.  Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.

Authors:  Hisato Takagi; Hideaki Manabe; Norikazu Kawai; Shin-nosuke Goto; Takuya Umemoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2009-04-20

5.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Authors:  Dean A Fergusson; Paul C Hébert; C David Mazer; Stephen Fremes; Charles MacAdams; John M Murkin; Kevin Teoh; Peter C Duke; Ramiro Arellano; Morris A Blajchman; Jean S Bussières; Dany Côté; Jacek Karski; Raymond Martineau; James A Robblee; Marc Rodger; George Wells; Jennifer Clinch; Roanda Pretorius
Journal:  N Engl J Med       Date:  2008-05-14       Impact factor: 91.245

Review 6.  Aprotinin revisited.

Authors:  Abe Deanda; Bruce D Spiess
Journal:  J Thorac Cardiovasc Surg       Date:  2012-07-15       Impact factor: 5.209

7.  Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.

Authors:  M Levi; M E Cromheecke; E de Jonge; M H Prins; B J de Mol; E Briët; H R Büller
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

8.  Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.

Authors:  Kenichi A Tanaka; Fania Szlam; Nobuyuki Katori; J David Vega; Jerrold H Levy
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

9.  Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.

Authors:  S E Fremes; B I Wong; E Lee; R Mai; G T Christakis; R F McLean; B S Goldman; C D Naylor
Journal:  Ann Thorac Surg       Date:  1994-12       Impact factor: 4.330

Review 10.  Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.

Authors:  Brian Hutton; Lawrence Joseph; Dean Fergusson; C David Mazer; Stan Shapiro; Alan Tinmouth
Journal:  BMJ       Date:  2012-09-11
View more
  2 in total

1.  Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

Authors:  Albert Farrugia; Declan Noone; Uwe Schlenkrich; Steffen Schlenkrich; Brian O'Mahony; Josephine Cassar
Journal:  J Blood Med       Date:  2015-06-15

Review 2.  Antifibrinolytics and cardiac surgery: The past, the present, and the future.

Authors:  Naresh K Aggarwal; Arun Subramanian
Journal:  Ann Card Anaesth       Date:  2020 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.